Ignite Creation Date:
2024-05-05 @ 5:20 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00430482
Status:
COMPLETED
Last Update Posted:
2019-07-10
First Post:
2007-01-31
Brief Title:
Stress Distress Intolerance and Drug Dependence
Sponsor:
Boston University Charles River Campus
Organization:
Boston University Charles River Campus
Study Overview
Official Title:
Stress Distress Intolerance and Drug Dependence
Status:
COMPLETED
Status Verified Date:
2019-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to evaluate the relative efficacy of a novel treatment CBT-IC versus a standard individual drug-counseling treatment The novel treatment emphasizes exposure to emotional cues for drug use as part of a comprehensive yet brief treatment strategy These treatments are delivered to opiate-dependent often poly-substance dependent individuals in a comprehensive methadone maintenance program who have failed to respond adequately to current treatments
Detailed Description:
This study study is designed to test further the efficacy of Cognitive-Behavior Therapy for Interoceptive Cues CBT-IC - a treatment with a central focus on enhancing a patients tolerance to the myriad forms of distress-sadness boredom anxiety withdrawal sensations etc-that are linked to the stressful lives of drug-dependent individuals and breaking the link between these emotional cues and drug-related attempts to avoid emotional distress for intervening with chronically-stressed and treatment-resistant opiate-dependent outpatients Features of this study of particular relevance to to RFA DA-04-001 include 1 a focus on opiate-dependent patients undergoing chronic stress 2 a model for the way in which chronic stress translates into chronic drug use 2 a focus on the way in which stress-related symptoms serve as trigger for drug use 3 a focus on both mediators and moderators of treatment that will inform treatment-matching efforts including a focus on gender differences and emotional avoidancedistress intolerance and 4 the examination of treatment outcome in a Stage II treatment trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01DA017904 | NIH | None | httpsreporternihgovquickSearchR01DA017904 |